See the Full Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Cannes Film Festival
Baseball
Social Media
Natural Disasters
Wrestling
WWE
NCAA
Twitter
Education
Instagram
Published • loading... • Updated

Peninsula biotech startup's buyout aims to reshape landscape for cardiovascular medicine

Summary by BizToc
"The heart is a fount of information," said Kardigan CEO Tassos Gianakakos, who sold heart drugmaker MyoKardia nearly five years ago for $13.1 billion.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
BizTocBizToc

Peninsula biotech startup's buyout aims to reshape landscape for cardiovascular medicine

"The heart is a fount of information," said Kardigan CEO Tassos Gianakakos, who sold heart drugmaker MyoKardia nearly five years ago for $13.1 billion.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

BizToc broke the news in on Wednesday, April 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Peninsula

Peninsula

News
For You
SearchBlindspotLocal